Cantor Fitzgerald Weighs in on Neos Therapeutics, Inc.’s FY2017 Earnings (NEOS)
Neos Therapeutics, Inc. (NASDAQ:NEOS) – Research analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for shares of Neos Therapeutics in a report released on Tuesday. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of ($3.00) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. Cantor Fitzgerald also issued estimates for Neos Therapeutics’ FY2018 earnings at ($1.47) EPS.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Tuesday, May 9th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.07. The company had revenue of $5.63 million during the quarter. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%.
Other analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Saturday, June 3rd. BMO Capital Markets reissued an “outperform” rating and issued a $15.00 price target on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Finally, ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.40.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.70 on Thursday. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $9.60. The firm’s 50-day moving average price is $7.22 and its 200-day moving average price is $6.94. The stock’s market cap is $151.15 million.
A number of institutional investors have recently modified their holdings of NEOS. Russell Investments Group Ltd. acquired a new position in shares of Neos Therapeutics during the fourth quarter valued at approximately $545,000. Teachers Advisors LLC boosted its position in shares of Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Neos Therapeutics by 151.8% in the first quarter. Columbus Circle Investors now owns 106,520 shares of the company’s stock valued at $767,000 after buying an additional 64,216 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after buying an additional 27,174 shares in the last quarter. Finally, Falcon Point Capital LLC boosted its position in shares of Neos Therapeutics by 3.1% in the first quarter. Falcon Point Capital LLC now owns 88,279 shares of the company’s stock valued at $636,000 after buying an additional 2,691 shares in the last quarter. 33.71% of the stock is owned by institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.